Galantamine is indicated for the treatment of mild to moderate dementia of the Alzheimer’s type.

Alzheimer's Disease

• Galantamine extended release: 8 mg/day in the morning is the recommended starting dose; after at least 4 weeks, increase to the initial maintenance dose of 16 mg/day. After a minimum of four weeks at 16 mg/day, the dosage may be increased to 24 mg/day based on clinical benefit and tolerability.
• Conversion from Galantamine tablets and oral solution to Galantamine extended release should take place at the same daily dosage, with the last dose of Galantamine tablets/oral solution taken in the evening and the first dose of Galantamine extended release taken the following morning.
• Galantamine tablets and oral solution: 4 mg twice daily as a starting dose; 8 mg twice daily as an initial maintenance dose after at least 4 weeks. After a minimum of four weeks at 8 mg twice daily, the dosage may be increased to 12 mg twice daily based on clinical benefit and tolerability.
• Take with meals and drink plenty of fluids during treatment.
• Hepatic impairment: for moderate hepatic impairment, do not exceed 16 mg/day; do not use in patients with severe hepatic impairment 
• Renal impairment: should not exceed 16 mg/day for creatinine clearance 9 to 59 mL/min; do not use in patients with creatinine clearance less than 9 mL/min

The most common adverse reactions were-

• nausea
• vomiting
• diarrhea
• dizziness
• headache
• decreased appetite

Nausea

Headache

Anorexia

Diarrhea

• Serious skin reactions: discontinue as soon as a skin rash appears.
• Because of vagotonic effects on the sinoatrial and atrioventricular nodes, all patients should be considered at risk for adverse effects on cardiac conduction, including bradycardia and AV block.
• Active or occult gastrointestinal bleeding: keep an eye on it, especially if you have a family history of ulcers.
• Cholinomimetics have the potential to obstruct bladder outflow.
• In patients with a history of severe asthma or obstructive pulmonary disease, keep an eye out for respiratory adverse events.